Global SERD Therapeutics Market Size is valued at USD 1339.0 Mn in 2024 and is predicted to reach USD 2108.7 Mn by the year 2034 at a 4.8% CAGR during the forecast period for 2025-2034.
Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD treats estrogen receptor-positive breast cancer. SERD therapy can be used as both monotherapies and in combination with other therapeutic agents. Many key market players are engaged in developing new breast cancer therapies that would propel the growth of this market.
Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, the rising number of clinical trials, and increasing investments by key players in the development of promising treatments. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market during the forecast period. However, the high price of devices, complex procedures, lack of strict government laws, and resistance to endocrine Therapy are limiting the growth of this market.
The SERD therapeutics market is segmented into Products, Route of Administration, Indication and Region. On the basis of Products, market is segmented into Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products. The Route of Administration segments consists of Intramuscular, Oral, Infusion, Subcutaneous, Parenteral, and Other. On the basis of Indications, segment includes ER-positive, HER2-negative, ESR1-mutated, advanced or metastatic breast cancer and Other.
Regionally, the SERD therapeutics market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, major market players, and the fast adaption of advanced technologies.
Major vital Players in the SERD therapeutics market are Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, and List of Other Prominent Players.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 1339.0 Mn |
| Revenue Forecast In 2034 | USD 2108.7 Mn |
| Growth Rate CAGR | CAGR of 4.8% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, By Route of Administration, By Indication |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, Genentech, Olema Pharmaceuticals, Aragon Pharmaceuticals, Sun Pharma Advanced Research Company, Shandong Luoxin Pharmaceutical Zeno Alpha, Atossa Therapeutics, Evestra and Others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Products
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Route Of Administration
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Indication
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
North America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Europe SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Latin America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Competitive Landscape
Latest Strategic Developments
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global SERD Therapeutics Market Snapshot
Chapter 4. Global SERD Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Key Trends in the Market
4.8. COVID 19 Impact Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Faslodex
5.2.2. Elacestrant
5.2.3. Camizestrant (AZD9833)
5.2.4. Giredestrant (GDC-9545)
5.2.5. Imlunestrant (LY3484356)
Other Pipeline Products
Chapter 6. SERD Therapeutics Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. Intramuscular
6.2.2. Oral
6.2.3. Infusion
6.2.4. Subcutaneous
6.2.5. Parenteral
6.2.6. Other
Chapter 6. SERD Therapeutics Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. By Indication Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
7.2.1. ER-positive
7.2.2. HER2-negative
7.2.3. ESR1-mutated advanced or metastatic breast cancer.
7.2.4. Other
Chapter 8. SERD Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
8.1.3. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
8.1.4. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.2.3. Europe SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.2.4. Europe SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.8. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.3.3. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.3.4. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.4.3. Latin America SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.4.4. Latin America SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.5.3. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.5.4. MEA revenue SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global SERD Therapeutics Market Snapshot
Chapter 4. Global SERD Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Key Trends in the Market
4.8. COVID 19 Impact Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Faslodex
5.2.2. Elacestrant
5.2.3. Camizestrant (AZD9833)
5.2.4. Giredestrant (GDC-9545)
5.2.5. Imlunestrant (LY3484356)
5.2.6. Other Pipeline Products
Chapter 6. SERD Therapeutics Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. Intramuscular
6.2.2. Oral
6.2.3. Infusion
6.2.4. Subcutaneous
6.2.5. Parenteral
6.2.6. Other
Chapter 7. SERD Therapeutics Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. By Indication Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
7.2.1. ER-positive
7.2.2. HER2-negative
7.2.3. ESR1-mutated advanced or metastatic breast cancer.
7.2.4. Other
Chapter 8. SERD Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
8.1.3. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
8.1.4. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.2.3. Europe SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.2.4. Europe SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.8. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.3.3. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.3.4. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.4.3. Latin America SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.4.4. Latin America SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.5.3. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.5.4. MEA revenue SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Amneal Pharmaceuticals Inc
8.2.2. AstraZeneca, Plc.
8.2.3. Dr. Reddy’s Laboratories
8.2.4. Eli Lilly and Company
8.2.5. G1 Therapeutics, Inc.
8.2.6. Glenmark Pharmaceuticals
8.2.7. HBT Labs, Inc
8.2.8. Hoffmann-La Roche AG
8.2.9. InventisBio
8.2.10. Novartis AG
8.2.11. Radius Health
8.2.12. Sanofi S.A.
8.2.13. Teva Pharmaceutical Industries Ltd.
8.2.14. Zenopharm LLC.
8.2.15. Zentalis Pharmaceuticals
8.2.16. Genentech
8.2.17. Olema Pharmaceuticals
8.2.18. Aragon Pharmaceuticals
8.2.19. Sun Pharma Advanced Research Company
8.2.20. Shandong Luoxin Pharmaceutical
8.2.21. Zeno Alpha
8.2.22. Atossa Therapeutics
8.2.23. Evestra
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Products
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Route Of Administration
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Indication
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
North America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Europe SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Latin America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Competitive Landscape
Latest Strategic Developments